Christian Peschel

Christian Peschel's AcademicInfluence.com Rankings

Christian Peschel

Computer Science

#6997

World Rank

#7370

Historical Rank

Machine Learning

#2446

World Rank

#2478

Historical Rank

Artificial Intelligence

#2731

World Rank

#2774

Historical Rank

Database

#4063

World Rank

#4225

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Christian Peschel's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science Stanford University

Similar Degrees You Can Earn

Why Is Christian Peschel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christian Peschel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved survival with ipilimumab in patients with metastatic melanoma. (2010) (13093)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) (1196)
Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity (2006) (808)
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. (2007) (774)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. (2003) (508)
A bioactive designer cytokine for human hematopoietic progenitor cell expansion (1997) (500)
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry (2016) (485)
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study (2002) (481)
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β production (2010) (441)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey (2015) (423)
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. (2001) (376)
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. (2008) (347)
The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. (2012) (338)
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. (2000) (323)
IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. (1988) (314)
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. (2014) (309)
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. (2002) (292)
Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity (1998) (289)
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. (2000) (237)
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production (vol 11, pg 63, 2010) (2014) (226)
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. (2005) (221)
Effects of B cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells. (1987) (213)
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. (2010) (211)
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. (2009) (211)
XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. (2014) (208)
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. (2009) (202)
The Nlrp3 inflammasome regulates acute graft-versus-host disease (2013) (186)
Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. (2005) (184)
Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells (2009) (184)
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. (2003) (177)
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (2010) (175)
18F-FDG PET–Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial (2011) (172)
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma (2015) (170)
Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6–sIL-6R Double Transgenic Mice (1997) (166)
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. (2005) (164)
Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma (2007) (164)
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. (2004) (163)
Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG (2007) (163)
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). (2005) (160)
Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy (2009) (159)
Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. (1996) (158)
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. (2004) (147)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. (2003) (142)
The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma (2010) (141)
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. (2004) (138)
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer (2007) (138)
Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity (2016) (136)
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells (2004) (136)
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. (2007) (130)
Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. (2002) (127)
Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo (2013) (126)
The Bcl10–Malt1 complex segregates FcɛRI-mediated nuclear factor κB activation and cytokine production from mast cell degranulation (2006) (125)
Endothelial‐like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction (2005) (124)
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. (2016) (123)
Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab (2006) (122)
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back (2003) (115)
Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib (2011) (112)
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. (2009) (110)
Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes (2009) (110)
Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. (2000) (108)
Bcl10 and Malt1 control lysophosphatidic acid-induced NF-κB activation and cytokine production (2007) (107)
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia (2005) (105)
Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27 (2002) (104)
Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. (2011) (102)
Role for the Adaptor Protein Grb10 in the Activation of Akt (2002) (101)
Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients (2005) (99)
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. (2005) (97)
Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. (1994) (94)
Interferon‐induced programmed death‐ligand 1 (PD‐L1/B7‐H1) expression increases on human acute myeloid leukemia blast cells during treatment (2014) (94)
Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production. (2008) (93)
SMIF, a Smad4-interacting protein that functions as a co-activator in TGFβ signalling (2002) (93)
MALT1 directs B cell receptor–induced canonical nuclear factor-κB signaling selectively to the c-Rel subunit (2007) (92)
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. (2010) (89)
Long‐Term Maintenance of Hematopoietic Stem Cells Does Not Require Contact with Embryo‐Derived Stromal Cells in Cocultures (2005) (87)
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients (2016) (86)
Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care (2017) (86)
NIPA Defines an SCF-Type Mammalian E3 Ligase that Regulates Mitotic Entry (2005) (84)
RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury (2017) (84)
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer (2005) (80)
SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma (2012) (80)
Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells (2004) (80)
Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. (2007) (78)
Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. (2005) (77)
Secreted frizzled-related protein 1 extrinsically regulates cycling activity and maintenance of hematopoietic stem cells. (2009) (76)
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer (2003) (76)
Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA (2013) (76)
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1 (2011) (75)
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. (2003) (74)
A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL (2009) (71)
Novel markers of mesenchymal stem cells defined by genome-wide gene expression analysis of stromal cells from different sources. (2010) (70)
Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck (2011) (70)
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. (2004) (70)
Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. (2014) (69)
Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine (2008) (68)
Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter‐related infections in patients with haemato‐oncological diseases: a prospective observational study (2003) (68)
How the niche regulates hematopoietic stem cells. (2010) (68)
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). (2006) (68)
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107 (2005) (68)
SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML. (2012) (66)
The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome. (2013) (65)
Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells (1993) (64)
Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer model (2014) (64)
Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial (2011) (64)
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (2011) (63)
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial (2005) (61)
Formin-like 1 (FMNL1) Is Regulated by N-terminal Myristoylation and Induces Polarized Membrane Blebbing* (2009) (61)
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia (2014) (61)
Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain (2002) (60)
Association of Bcr-Abl with the Proto-oncogene Vav Is Implicated in Activation of the Rac-1 Pathway* (2002) (60)
Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer (2011) (60)
Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA)* (2003) (59)
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. (2007) (59)
Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. (2006) (59)
Monoclonal antibodies to human myelomonocyte differentiation antigens in the diagnosis of acute myeloid leukemia (1984) (58)
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment (2007) (57)
Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. (2000) (57)
The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells1 (2001) (56)
Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma (2002) (56)
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib (2013) (55)
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics (2018) (54)
Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis (2014) (54)
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma (2005) (53)
Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. (1996) (51)
Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3): Results of a Phase 1/2 Study (2009) (51)
Induction Chemotherapy in Barrett Cancer: Influence on Surgical Risk and Outcome (2007) (50)
Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal (1996) (50)
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia (2016) (50)
Use of Complementary and Alternative Medicine (CAM) as Part of the Oncological Treatment: Survey about Patients’ Attitude towards CAM in a University-Based Oncology Center in Germany (2016) (49)
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells (2008) (49)
Bcr‐Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors (1998) (49)
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. (2020) (49)
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. (2002) (48)
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors (2011) (47)
In Vivo Osteoprogenitor Potency of Human Stromal Cells from Different Tissues Does Not Correlate with Expression of POU5F1 or Its Pseudogenes (2008) (47)
Interleukin-4 induces a substance in bone marrow stromal cells that reversibly inhibits factor-dependent and factor-independent cell proliferation. (1989) (47)
Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer (2012) (47)
The oncogenic fusion protein nucleophosmin–anaplastic lymphoma kinase (NPM–ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model (2003) (46)
USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B‐cell lymphoma (2016) (46)
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib (2006) (46)
Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group (2007) (46)
Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL (2006) (46)
Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia (2018) (45)
Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. (2001) (44)
Immuno-PET Imaging of Engineered Human T Cells in Tumors. (2016) (43)
Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia. (1995) (43)
Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens (2004) (43)
Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. (1996) (42)
A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). (2006) (41)
A Cell-Based Screening Strategy That Predicts Mutations in Oncogenic Tyrosine Kinases: Implications for Clinical Resistance in Targeted Cancer Treatment (2005) (41)
[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner (2012) (41)
A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma (2016) (40)
Niche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cells (2017) (40)
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion (2012) (39)
Recruitment of PKC-βII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70 (2010) (39)
Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders. (1996) (38)
Allorestricted T lymphocytes with a high avidity T‐cell receptor towards NY‐ESO‐1 have potent anti‐tumor activity (2009) (38)
Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment (2008) (37)
Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells1 (2000) (37)
Mitotic Entry: A Matter of Oscillating Destruction (2005) (37)
PD‐1 expression on Melan‐A‐reactive T cells increases during progression to metastatic disease (2012) (37)
Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. (2011) (36)
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial (2009) (36)
FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. (2012) (36)
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dos (2013) (36)
Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. (1998) (35)
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells (2003) (34)
The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. (2000) (34)
Skp2 Directs Myc-Mediated Suppression of p27Kip1 yet Has Modest Effects on Myc-Driven Lymphomagenesis (2010) (33)
Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results (2007) (33)
GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. (2008) (33)
Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. (1993) (33)
Sustained Expansion and Transgene Expression of Coagulation Factor VIII–Transduced Cord Blood–Derived Endothelial Progenitor Cells (2003) (33)
Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. (1996) (32)
A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma (2011) (32)
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial (2008) (32)
Regulation and function of the CGRP receptor complex in human granulopoiesis. (2002) (32)
Myc suppression of Nfkb2 accelerates lymphomagenesis (2010) (31)
Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib (2005) (31)
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose (2019) (31)
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro (2011) (31)
GP130 activation induces myeloma and collaborates with MYC. (2014) (31)
Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. (2003) (30)
A limited number of 5-azacitidine cycles can be effective treatment in MDS (2009) (30)
Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast. (2000) (30)
Characterization of Ggrb4, an adapter protein interacting with Bcr-Abl. (2000) (30)
A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM). (2015) (29)
Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial. (2009) (29)
Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option (2005) (29)
Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: Results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia (1995) (28)
Multisite Phosphorylation of Nuclear Interaction Partner of ALK (NIPA) at G2/M Involves Cyclin B1/Cdk1*♦ (2007) (28)
Serious outbreak of human metapneumovirus in patients with hematologic malignancies (2016) (28)
Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2009) (28)
A Single TCRα-Chain with Dominant Peptide Recognition in the Allorestricted HER2/neu-Specific T Cell Repertoire (2009) (28)
Recruitment of PKC-Beta to Lipid Rafts Mediates Apoptosis-Resistance in Chronic Lymphocytic Leukemia Expressing Zap-70. (2009) (28)
In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET (2017) (28)
Proteomic investigation of the interactome of FMNL1 in hematopoietic cells unveils a role in calcium-dependent membrane plasticity. (2013) (28)
CD133-enriched CD34(-) (CD33/CD38/CD71)(-) cord blood cells acquire CD34 prior to cell division and hematopoietic activity is exclusively associated with CD34 expression. (2007) (28)
Bone marrow involvement in follicular lymphoma: Comparison of histology and flow cytometry as staging procedures (2006) (27)
APC/CCdh1-Mediated Degradation of the F-Box Protein NIPA Is Regulated by Its Association with Skp1 (2011) (27)
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL (2014) (27)
Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance (2016) (27)
Preferential proliferation of immature B lineage cells in long-term stromal cell-dependent cultures with IL-4. (1989) (26)
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl‐2 expression (2010) (26)
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis (2019) (26)
A micro agar culture system for cloning human erythropoietic progenitors in vitro. (1982) (26)
Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. (2011) (26)
Phosphorylation of Grb10 Regulates Its Interaction with 14-3-3* (2005) (26)
Clinical applications of cytokines. (1994) (26)
A20 Restrains Thymic Regulatory T Cell Development (2017) (25)
Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. (2003) (25)
Induction of macrophage-inflammatory protein 1alpha (MIP-1alpha) by interferon-alpha. (1998) (25)
Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. (2004) (24)
Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors (2010) (24)
Adjunctive interferon-α-2c in stage IIIb/Iv small-cell lung cancer : a phase III trial (1997) (24)
Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells (2014) (24)
Bcl10/Malt1 Signaling Is Essential for TCR-Induced NF-κB Activation in Thymocytes but Dispensable for Positive or Negative Selection1 (2007) (23)
Melanoma-Reactive Class I-Restricted Cytotoxic T Cell Clones Are Stimulated by Dendritic Cells Loaded with Synthetic Peptides, but Fail to Respond to Dendritic Cells Pulsed with Melanoma-Derived Heat Shock Proteins In Vitro1 (2004) (23)
Inhibition of interleukin-11 by interferon-alpha in human bone marrow stromal cells. (1996) (23)
Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia. (2016) (22)
A regulatory role of activated T‐lymphocytes on human megakaryocytopoiesis in vitro (1985) (22)
The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care — an observational analysis on non-small-cell lung cancer patients (2013) (22)
Role of B cell stimulatory factor 1/interleukin 4 in clonal proliferation of B cells. (1987) (22)
Radiotherapy and Chemotherapy for Myoepithelioma of the Sellar Region (2005) (22)
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. (2008) (22)
Regulation of the cytokine network by interferon: a potential mechanism of interferon in chronic myelogenous leukemia. (1993) (22)
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation (2008) (22)
Interferon-a Stimulates Production of Interleukin-10 in Activated CD4+ T Cells and Monocytes (2002) (22)
Effects of imatinib on bone marrow engraftment in syngeneic mice (2002) (22)
Peripheral primitive neuroectodermal tumor of the stomach in a 14-year-old boy: a case report (2004) (22)
CTLs Directed against HER2 Specifically Cross-React with HER3 and HER41 (2008) (21)
Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma (2014) (21)
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma (2015) (21)
MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study. (2016) (21)
Stroma-Derived Connective Tissue Growth Factor Maintains Cell Cycle Progression and Repopulation Activity of Hematopoietic Stem Cells In Vitro (2015) (21)
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. (2007) (21)
Card9 controls Dectin‐1‐induced T‐cell cytotoxicity and tumor growth in mice (2017) (20)
Oncostatin M‐Mediated Regulation of KIT‐Ligand‐Induced Extracellular Signal‐Regulated Kinase Signaling Maintains Hematopoietic Repopulating Activity of Lin−CD34+CD133+ Cord Blood Cells (2008) (20)
Induction of the pro-myelocytic leukaemia gene by type I and type II interferons. (1998) (20)
Induction of interferon regulatory factors, 2′‐5′ oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness (1996) (20)
Interleukins. Clinical pharmacology and therapeutic use. (1994) (20)
Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice. (2010) (20)
Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach (2006) (20)
Cks1 Is Required for Tumor Cell Proliferation but Not Sufficient to Induce Hematopoietic Malignancies (2012) (20)
Human erythropoiesis in vitro and the source of burst-promoting activity in a serum-free system. (1986) (20)
Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST) (2019) (19)
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer. (2004) (19)
Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase (2012) (19)
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. (2018) (19)
Effect of Immunostimulatory CpG-Oligonucleotides in Chronic Lymphocytic Leukemia B Cells (2001) (19)
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib (2007) (18)
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile (2018) (18)
Effect of interleukin‐3 pretreatment on granulocyte/macrophage colony‐stimulating factor induced mobilization of circulating haemopoietic progenitor cells (1995) (18)
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo (2003) (17)
Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer (2014) (17)
A miniaturized agar culture system for cloning human erythropoietic progenitor cells. (1984) (17)
Protein Kinase C-β Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in Vivo (2012) (17)
Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study. (1998) (17)
Cytokine therapy of neoplastic and inflammatory disease. (1993) (17)
Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals. (1999) (17)
Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo (1996) (17)
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib (2010) (16)
Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles (2008) (16)
Use of a cocktail of monoclonal antibodies and human complement in selective killing of acute lymphocytic leukemia cells (1986) (16)
gp130-stimulating designer cytokine Hyper-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells. (2001) (16)
Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer (2011) (16)
Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line Treatment (2013) (15)
Expression of cyclin E in resting and activated B‐chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target (2004) (15)
Prdm6 Is Essential for Cardiovascular Development In Vivo (2013) (15)
Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status (2010) (15)
Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (2008) (14)
Very Severe Iron-Deficiency Anemia in a Patient with Celiac Disease and Bulimia Nervosa: A Case Report (2005) (14)
Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma (2014) (14)
Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival (2013) (14)
Clonal growth of human megakaryocytic progenitor cells in a micro-agar culture system: simultaneous proliferation of megakaryocytic, granulocytic, and erythroid progenitor cells (CFU-M, CFU-C, BFU-E) and T-lymphocytic colonies (CFU-TL). (1983) (14)
Human interleukin-4 enhances stromal cell-dependent hematopoiesis: costimulation with stem cell factor. (1994) (14)
Isolation of human MHC class II‐restricted T cell receptors from the autologous T‐cell repertoire with potent anti‐leukaemic reactivity (2012) (13)
Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status. (2008) (13)
Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden. (1994) (13)
Grb10 is involved in BCR-ABL-positive leukemia in mice (2014) (13)
Antibody-based targeted therapy for gastric cancer (2005) (13)
Cks1 Promotion of S Phase Entry and Proliferation Is Independent of p27Kip1 Suppression (2012) (12)
Myelopoiesis of human bone marrow cells in a micro-agar culture system: comparison of two sources of colony stimulating activity (CSA). (1983) (12)
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations (2017) (12)
Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/II trial (2005) (12)
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma. (2006) (12)
Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy (2006) (12)
Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells (2006) (12)
Roquin Paralogs Differentially Regulate Functional NKT Cell Subsets (2017) (12)
Extracellular Signal-regulated Kinase 2 (ERK2) Mediates Phosphorylation and Inactivation of Nuclear Interaction Partner of Anaplastic Lymphoma Kinase (NIPA) at G2/M* (2012) (12)
Evaluation of the new continuous mononuclear cell collection protocol versus an older version on two different apheresis machines (2018) (11)
An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis. (2011) (11)
Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single‐center retrospective analysis (2017) (11)
The role of azacitidine in the management of myelodysplastic syndromes (MDS) (2009) (11)
Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors (2002) (11)
Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts. (2010) (10)
T14, A Non-modulating 150-Kd T Cell Surface Antigen (1986) (10)
Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells (2014) (10)
Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. (1997) (10)
Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib (2016) (10)
Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors (2014) (10)
Studies on differentiation of committed hemopoietic progenitor cells with monoclonal antibodies directed against myeloid differentiation antigens. (1985) (10)
Studies of myelopoiesis in vitro on blood and bone marrow cells of patients with acute leukemia in long-term remission. (1983) (10)
A micro-culture system for cloning human T lymphocytes in agar. (1981) (10)
Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors. (1995) (10)
[Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients]. (2003) (10)
Interferon‐α (IFN‐α) inhibits granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) expression at the post‐transcriptional level in murine bone marrow stromal cells (1995) (9)
Progressive preleukemia presenting amegakaryocytic thrombocytopenic purpura: association of the 5q- syndrome with a decreased megakaryocytic colony formation and a defective production of Meg-CSF. (1987) (9)
Proliferation and differentiation of human erythropoiesis in vitro: effect of different human lipoprotein species. (1988) (9)
Expression of receptors for atrial natriuretic peptide on the murine bone marrow-derived stromal cells. (1992) (9)
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia (2007) (9)
Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. (2004) (9)
FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes (2011) (9)
Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. (1996) (9)
Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients (1997) (9)
Chemotherapy-Induced Nausea and Vomiting in the Treatment of Gastrointestinal Tumors and Secondary Prophylaxis with Aprepitant (2009) (9)
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG) (2016) (9)
Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options. (2006) (8)
Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment (2014) (8)
Report of a male patient with brain metastases from breast cancer. (2003) (8)
MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) (8)
Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG). (2008) (8)
Loss of Sfrp2 in the Niche Amplifies Stress‐Induced Cellular Responses, and Impairs the In Vivo Regeneration of the Hematopoietic Stem Cell Pool (2016) (8)
Isolation and expansion of tumor-reactive cytotoxic T-cell clones for adoptive immunotherapy. (2005) (8)
Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization (2008) (8)
A20 deletion in T cells modulates acute graft‐versus‐host disease in mice (2017) (8)
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia – results of a phase-II trial (1998) (8)
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma (2014) (7)
Grb4/Nckβ Acts as a Nuclear Repressor of v-Abl-induced Transcription from c-jun/c-fosPromoter Elements* (2001) (7)
USP 9 X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma (2016) (7)
Hematopoietic growth factors are differentially regulated in monocytes and CD4+ T lymphocytes: influence of IFN-alpha and interleukin-4. (1998) (7)
cAMP analogues downregulate the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro. (1998) (7)
Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group (2015) (7)
Cancer clinical trials – Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC) (2018) (6)
Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells. (2001) (6)
Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia (1993) (6)
Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure. (2020) (6)
PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study. (2011) (6)
Characteristics and outcome of patients presenting to the emergency department after autologous/allogeneic stem cell transplantation (2017) (6)
Three-weekly docetaxel (T) plus capecitabine (X) in 1st and 2nd line metastatic esophageal cancer (MEC): Final Results of the phase II DACAPO Trial (2005) (6)
Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia. (1995) (6)
The role of erythropoietin, megakaryocyte colony-stimulating factor, and T-cell-derived factors on human megakaryocyte colony formation: evidence for T-cell-mediated and T-cell-independent stem cell proliferation. (1987) (6)
Restoration of transgene expression in hematopoietic cells with drug-selectable marker genes. (2002) (6)
Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET (2007) (6)
PET for Initial and Early Response Imaging in Mantle Cell Lymphoma (2011) (5)
Early ResponseAssessment Using 3 ¶-Deoxy-3 ¶-[ 18 F ] Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin ’ s Lymphoma (2007) (5)
An adult patient with Nijmegen Breakage Syndrome and Hodgkin's Lymphoma (2014) (5)
215 A randomized, multinational phase III study in first line metastatic and locally recurrent gastric cancer (MGC): CPT-11 plus 5-fluorouracil (5-FU)/leucovorin (LV) versus cisplatinum (CDDP) plus 5-FU (2003) (5)
Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure (2016) (5)
Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis (2019) (5)
Changes of the phenotype of erythroid progenitor cells (BFU‐E, CFU‐E) and their progenies during early steps of differentiation (1987) (5)
' s response to reviews Title : Myc suppression of Nfkb 2 accelerates lymphomagenesis (2010) (5)
BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma. (2004) (5)
4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results (2007) (5)
The Bcl10/Malt1 signaling pathway as a drug target in lymphoma. (2006) (5)
Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer. (2009) (5)
The Bcl 10 – Malt 1 complex segregates Fc ε RI-mediated nuclear factor κ B activation and cytokine production from mast cell degranulation (2006) (5)
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation (2013) (4)
Impact of response to chemotherapy and treating institution on survival in primary CNS lymphoma (PCNSL): Long-term results of the multicenter BMPD study. (2004) (4)
Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery. (2006) (4)
Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. (2004) (4)
Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients (2015) (4)
Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study (2015) (4)
production B and MAPK activation to selectively control cytokine κ via Carma1 for NF- Multiple ITAM-coupled NK cell receptors engage the Bcl10/Malt1 complex (2013) (4)
Individualized indication for neoadjuvant treatment based on metabolic response Assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in adenocarcinoma of the esophago-gastric junction (AEG) (2005) (4)
Smif (Smad4 Interacting Factor) Is a Negative Regulator of T Cell Activation and Autoimmunity In Vivo. (2009) (4)
Maintenance of hematopoietic stem cells does not require direct contact with embryo-derived stromal cells in co-cultures (2004) (4)
Regulatory elements of the leukaemia inhibitory factor (LIF) promoter in murine bone marrow stromal cells. (1999) (4)
Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies (2004) (4)
Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature (2014) (4)
[The STEMMAT-project as part of health initiative BayernAktiv: adult stem cells from umbilical cord and cord blood as alternative to embryonic stem cell research]. (2006) (4)
A case of acquired pure red cell anemia studied by cloning of erythroid progenitor cells in vitro. (1983) (4)
A New Method of Retroviral Lineage Specific Expression Utilizing the Cre/lox System Induces a T-Lymphoid Malignancy in a Mouse Model of ALCL. (2004) (4)
inhibitor nilotinib (AMN107) mutations to be associated with clinical resistance to the Abl kinase Bcr-Abl resistance screening predicts a limited spectrum of point (2011) (4)
Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial (2008) (4)
Oxaliplatin plus 5FU/folinic acid (FUFOX regimen) in 1st line metastatic gastric cancer (MGC). Results of the Multicenter Phase II STOMOX Trial (2005) (4)
In vitro growth of erythropoietic progenitor cells in long-term remission of acute leukemia. (1986) (4)
Regulation of hematopoietic growth factor production by genetically modified human bone marrow stromal cells expressing interleukin-1beta antisense RNA. (2001) (4)
Activity of Serono-AS703569, a Dual Inhibitor of Bcr-Abl and Aurora Kinases in Bcr-Abl Transformed Cells, Is Dependent On Aurora B Inhibition, and Is Not Affected by the Presence of the Highly Imatinib Resistant Bcr-Abl Mutation T315I. (2009) (4)
Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors? (2004) (4)
BCR-ABL P-Loop Deletion Detected in Imatinib-Resistant CML Patients Corresponds to Splice Variant Associated with L248V Point Mutation, Retains BCR-ABL Kinase Activity, and Responds to Dasatinib Treatment. (2006) (4)
Long‐term experiences in cryopreservation of mobilized peripheral blood stem cells using a closed‐bag system: a technology with potential for broader application (2015) (3)
Ruxolitinib Mediated Paradox JAK2 Hyperphosphorylation Is Due To The Protection Of Activation Loop Phosphotyrosines From Phosphatases (2013) (3)
NPM-ALK Induces Tumour Development in a Murine Model of Anaplastic Large Cell Lymphoma (ALCL) Independently of Bcl-3 Expression. (2007) (3)
IFN-alpha stimulates proliferation and cytokine secretion of CD40-stimulated B cell chronic lymphocytic leukemia cells in vitro. (1999) (3)
A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (2015) (3)
PET-MRI hybrid imaging in a rare case of B cell lymphoblastic lymphoma with musculoskeletal manifestation (2014) (3)
Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma (2012) (3)
Response to JAK 1/2 Inhibition in Patients with Corticosteroid-Refractory Acute Graft-Versus-Host Disease (2014) (3)
MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study. (2017) (3)
Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy (2010) (3)
Docetaxel, cisplatin and leucovorin/fluorouracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial (2007) (2)
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML) (2013) (2)
Combination of c-SRC and FLT3 Inhibitors Has An Additive Inhibitory Effect on FLT3 ITD but Not on FLT3 TKD Positive Cells (2010) (2)
34 AZACITIDINE DIRECTLY MODULATES FUNCTION OF MESENCHYMAL STROMAL CELLS TO ALTER BONE MARROW NICHE COMPOSTION AND SUPPRESS MALIGNANT HEMATOPOEITIC PROGENITORS IN MDS (2015) (2)
A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma (2017) (2)
[68Ga]Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma (2014) (2)
In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment (2015) (2)
Effect of human plasmalipoproteins on erythropoietic progenitor cells in serum-free cultures (1986) (2)
Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. (1996) (2)
Identification Of a Novel Mode Of Kinase Inhibitor Resistance In JAK2: JAK2 Inhibitor Resistance Is Mediated By The Generation Of 45-Kda JAK2 Variant Which Alters The Kinase Domain Structure (2013) (2)
Reactivity of Anti-Myeloid Monoclonal Antibodies with Committed Hematopoietic Precursor Cells (1986) (2)
mHealth in Oncology: A Patient Survey Evaluating the Acceptance of App-Assisted Cancer Treatment (2017) (2)
Tumor-Reactive T-Cells for Adoptive Immunotherapy (2006) (2)
Cationic lipide mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modulation of gene expression (1996) (2)
MTOR (mammalian target of rapamycin) inhibition with RAD001 induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitizes DLBCL cells to rituximab therapy. (2004) (2)
CFU-gm assay, cytochemical and electron microscopic studies in agar in patients with preleukemic syndrome and aplastic anemia. (1985) (2)
Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma (2016) (2)
Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using ( 18 F)Fluorothymidine-PET (2015) (2)
Peptide-Receptor Radiotherapy with CXCR4-Targeting Pentixather Reduces Leukemia Burden in Acute Leukemia PDX and Patients (2016) (2)
Cytokines in the pathophysiology and treatment of chronic B-cell malignancies (1995) (2)
Blood component use and associated costs after standard dose chemotherapy—a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany (2012) (2)
Molecular Mechanisms of JAK2V617F Oncogenic Activation: The JAK2- V617F Mutant Utilizes the SH2 Domain for Constitutive Kinase Activity in the Presence of Unstimulated Heterodimeric Cytokine Receptor. (2008) (2)
The Immunogenicity of BCR/ABL+ Cells Is Dominated by BCR/ABL-Regulated Antigens and Is Impaired by the Inhibition of BCR/ABL Kinase Activity. (2006) (2)
Cost analysis of febrile neutropenia (FN) management in three tumour types in Germany (2008) (1)
Cathepsin K maintains the number of lymphocytes in vivo (2020) (1)
27 BLOCKADE OF BCL-2 PROTEINS EFFICIENTLY INDUCES APOPTOSIS IN PROGENITOR CELLS OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS (2015) (1)
Evasion of Necroptosis and Inflammasome Activation Promotes Myeloid Leukemogenesis (2016) (1)
Identification of a Novel Mode of Kinase Inhibitor Resistance: An F604S Exchange in FIP1L1-PDGFRA Modulates FIP1L1-PDGFRA Protein Stability in a SHP-2 and SRC-Dependent Manner (2008) (1)
Bryostatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy. (2009) (1)
Induction of a T helper cell response against the tumor-associated antigen HER2 using monocyte-derived dendritic cells (2004) (1)
[An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes]. (2004) (1)
[New aspects of megakaryopoiesis]. (1983) (1)
Interferon-α as an Antagonist to Proinflammatory and Hematopoietic Cytokines (1994) (1)
[Bone marrow culture in aplastic anemia and preleukemias]. (1979) (1)
Sorafenib and Nilotinib Are Candidates to Overcome Imatinib Resistance in Myeloproliferation with FIP1L1-PDGFRA. (2009) (1)
Generation of Specific Resistance Profiles in FLT3-ITD and FIP1L1-PDGFRalpha towards Specifically Acting Tyrosine Kinase Inhibitors. (2006) (1)
FcεRI-mediated nuclear factor κB activation and cytokine production from mast cell degranulation (2006) (1)
Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2009) (1)
The Transcription Factors RUNX1/AML1 and RUNX3/AML2 Protect Bcr-Abl-Transformed B-Cells from Imatinib Induced Apoptosis. (2005) (1)
IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-p) (1993) (1)
Cathepsin K is required for maintenance and regeneration of lymphopoiesis in vivo (2020) (1)
NIPA Targets Nuclear Cyclin B1 in a Cell-Cycle Dependent Manner. (2004) (1)
[Proliferation of megakaryocytic precursor cells (CFU-M) in a micro-agar culture system]. (1984) (1)
[In vitro studies of clonable human B lymphocytes]. (1983) (1)
The Role of the Cytoplasmic RNA Sensor Retinoic Acid Inducible Gene- I (RIG-I) in Allogeneic Stem Cell Transplantation (2014) (1)
Role of SH2 Domain in JAK2-V617F Mediated Transformation. (2006) (1)
RIG-I-Induced Type I IFNs Promote Regeneration of the Intestinal Stem Cell Compartment during Acute Tissue Damage (2015) (1)
Detection of mutant-free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor (GIST) harboring activating mutations of C-Kit or PDGFRA. (2013) (1)
leukemia B cells production, and an immunogenic phenotype in chronic lymphocytic Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine (2013) (1)
Interferon-alpha (IFN-alpha) inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) expression at the post-transcriptional level in murine bone marrow stromal cells. (1995) (1)
FLT3 ITD and FLT3 Tyrosine Kinase Domain Mutants Induce Different Phenotypes in a Murine Bone Marrow Transplant Model. (2004) (1)
Abstract 19: Identification of a novel mode of kinase inhibitor resistance: An F604S exchange in FIP1L1-PDGFRA modulates FIP1L1-PDGFRA protein stability in a SHP-2 and SRC-dependent manner (2010) (1)
MCL-1 Critically Regulates Survival Of T-Lymphocyte Non-Hodgkin Lymphoma (2013) (1)
Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective “Dose”-Finding Study. (2007) (1)
T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST (2010) (1)
A prospective Multicenter study of the BMPD regimen with or without radiotherapy for primary CNS lymphoma. (2003) (1)
Change of tumor cell proliferation during R-CHOP chemotherapy of diffuse large B cell lymphoma (DLBCL) measured by 18FLT-PET (2006) (1)
The RIG-I Agonist 3pRNA Synergizes with Checkpoint Blockade in Cancer Immunotherapy (2015) (1)
Grb4/Nckbeta acts as a nuclear repressor of v-Abl-induced transcription from c-jun/c-fos promoter elements. (2001) (1)
Bone marrow histology and flow cytometry (FCM) as staging procedures in follicular lymphoma (FL) (2004) (1)
Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma (2012) (0)
Establishment of a T cell receptor biobank for patients with acute myeloid leukemia to be individually treated by genetically modified donor lymphocyte infusions after haploidentical stem cell transplantation (2015) (0)
Transfer of Human T-Cell Receptors (TCR) Containing Murine Chimeric Constant Beta-Gamma-Chain Sequences Reduces the Risk of Mixed Heterodimers and Shows Enhanced in Vitro-Accumulation of TCR-Tranduced Effector Cells. (2009) (0)
Generating of Human CD4+ and CD8+ T Lymphocytes toward NY-ESO-1 by T Cell Receptor (TCR) Modification and Transduction for Adoptive TCR Gene-Transfer (2008) (0)
Molecular cytokine regulation by interferon-α (IFN-α) in bone marrow stromal cells: A possible paracrine mode of action in chronic myeloid leukemia (CML) (1995) (0)
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dos (2013) (0)
NIPA Checkpoint Control In Oncogenic Transformation Is Dependent on p53 (2010) (0)
Activated Sumoylation Is a Hallmark Of Burkitt's Lymphoma and MYC Driven Cancer Leading To Synthetic Lethal Interactions With Sumoylation Inhibitors (2013) (0)
Induction of Apoptosis and Cell Cycle Arrest in Acute Myeloid Leukemia Cells by Histone Deacetylase Inhibitor, Suberoyl Hydroxamic Acid (SAHA): Lack of Cross-Resistance to Cytosine Arabinoside and Etoposide. (2004) (0)
Single agent cetuximab induces a decrease in the tumor glucose-uptake measured by 18F-fluorodeoxyglucose positron emission tomography in advanced squamous cell carcinoma of the esophagus (2008) (0)
Identification of CXCR4 Expression By Targeted PET/MR Imaging in Patients with Acute Myeloid Leukemia (AML) (2015) (0)
Card9 controls Dectin1induced Tcell cytotoxicity and tumor growth in mice (2017) (0)
P-112 Response to azacitidine is independent of TP53 mutations in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia (2013) (0)
A Single TCRa-Chain with Dominant Peptide Recognition in the Allorestricted HER2/neu-Specific T Cell Repertoire (2009) (0)
Redirecting Human T Lymphocytes toward Tumor-Associated Antigens by T Cell Receptor (TCR) Replacement. (2006) (0)
TDB) activates the Nlrp3 inflammasome (2012) (0)
Identification of the Lymphoma-Initiating Cell Population in a T Cell Lymphoma Mouse Model Resembling Human Anaplastic Large Cell Lymphoma (2014) (0)
Mutants de domaines de la kinase de l'ABL (2002) (0)
In-vivo imaging of proliferation in patients with mantle cell lymphoma and correlation with Ki-67 protein expression (2011) (0)
Impact of pathologic complete response to preoperative docetaxel-based chemotherapy on disease-free survival in esophagogastric adenocarcinoma. (2013) (0)
Mutant of the kinase domain of ABL (2002) (0)
Proteinkinase C-β Inhibitors Mitigate Microenvironment-Mediated Survival Of CLL Cells and Sensitise Malignant B Cells To Cytotoxic Drugs (2013) (0)
Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma (2012) (0)
Myc Commands an Aurora Kinase – Sumoylation Circuit Required for B Cell Lymphoma Growth and Survival (2014) (0)
Role of Cytokines in the Regulation of Malignant B Cell Proliferation (1994) (0)
Acquisition of CD34 Correlates with Increased Hematopoietic and Self Renewal Activity of CD34−CD133+ Cord Blood Cells. (2004) (0)
Resource Use and Costs Associated with Routine Management of Febrile Neutropenia in German Hospitals. (2007) (0)
Sfrp2 from the niche is required to maintain the regeneration of the hematopoietic stem cell pool (2017) (0)
Metabolic response-guided treatment individualization in neoadjuvant therapy of locally advanced adenocarcinoma of the esophagogastric junction (AEG) (2007) (0)
Efficacy, tolerability and improvement of symptoms in heavily pretreated patients with locally advanced or metastatic non-small-cell lung cancer treated with gefitinib ('Iressa', ZD1839) (2003) (0)
Analysis of mice with deficiencies in their hematopoietic niche (2007) (0)
Lentivirally Transduced Human Cord Blood CD34 + FLT3-ITD + Cells Induce Murine Acute Leukemia in the NOD/SCID Transplantation Model. (2012) (0)
Two weeks of single agent cetuximab (CET) induce a decrease in the tumor glucose-uptake measured by 18FDG-PET during neoadjuvant treatment of locally advanced squamous cell carcinoma (SCC) of the esophagus (2008) (0)
Interferon-alpha as an antagonist to proinflammatory and hematopoietic cytokines. (1994) (0)
Significance of the IL-3 Receptor Beta Chain (IL-3Rbc) for FLT3-ITD Dependent Oncogeneic Signaling in AML (2015) (0)
Early prediction of response in patients with NSCLC stage III and IV during platin based chemotherapy by FDG-PET (2001) (0)
Interferon regulatory factor 4 is not required for induction of chronic myeloid leukaemia-like myeloproliferative disease by Bcr/Abl in mice (2005) (0)
Multisite Phosphorylation of NIPA at G2/M. (2007) (0)
Raf1 Is Required for Induction of a Bcr-Abl Positive CML Like Myeloproliferative Disease in Mice (2008) (0)
Secreted Mediators of Self-Renewal of Hematopoietic Stem Cells Identified Using Bio-Informatic Analysis of Co-Cultures of HSC and Stromal Cells. (2012) (0)
Geminin Is a Newly Identified Cks1 Interaction Partner and Overexpressed in a Murine Model During Lymphomagenesis (2012) (0)
The Oncogenic Fusionprotein NPM-ALK Cooperates with Bcl2 To Induce T-Cell Lymphomas in Mice. (2006) (0)
Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST) (2023) (0)
FLT3-ITD Interacts with and Phosphorylates IL-3β, and JAK1/2 Dependent IL-3β Activation Bypasses FLT3-ITD in FLT3 Kinase Independent Inhibitor Resistance in Vitro: Evidence for the Significance of IL-3β for FLT3-ITD Dependent Oncogeneic Signaling in AML. (2012) (0)
Physicians Poster Sessions (2013) (0)
Control of Meiotic and Mitoic Progression by the F-Box Protein NIPA In Vivo. (2006) (0)
P-016 Resistance to apoptosis in high-risk myelodysplastic syndrome can be overcome by pro-apoptotic drug treatment using ABT-737 (2013) (0)
Transduced Dendritic Cells Antigen HER2 Using Retrovirally Clones Specific for the Tumor-Associated The Generation of Both T Killer and Th Cell (2001) (0)
NIPA Deficiency Leads To Acceleration Of The Lymphoma Development In EµMyc Mice (2013) (0)
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with Proteinkinase Cδ Short titel: Constitutively activated PI-3 kinase in B-CLL (2002) (0)
Generation and Characterization Of a CD30 Positive T-Cell Lymphoma Mouse Model Resembling Human Anaplastic Large Cell Lymphoma (2013) (0)
Changes in the tumor glucose-uptake measured by 18F-FDG PET with two weeks of single-agent cetuximab in localized squamous cell carcinoma of the esophagus. (2013) (0)
antiapoptotic signaling pathway large-cell lymphoma activates the phosphatidylinositol 3-kinase / Akt anaplastic lymphoma kinase associated with anaplastic − Nucleophosmin (2000) (0)
The JAK2V617F mutation is rare in reactive lymphoid infiltrates of chronic myeloproliferative disorders (cMPD) and absent in concomitant non-Hodgkin lymphomas (NHL) (2007) (0)
NIPA Checkpoint Control Is Essential for Efficient Oncogenic Transformation by C-Myc (2008) (0)
Progenitor Cells Hemopoietic + Derived from CD34 Retrovirally Transduced Dendritic Cells the Tumor-Associated Antigen HER2 Using Generation of Tumor-Reactive CTL Against (2000) (0)
IL-4 protects B-CLL cells from spontaneous and drug induced apoptosis by regulation of pro- and antiapoptotic proteins and PKCd. (2003) (0)
JAK1/2 Inhibition Suppresses T Cell Proliferation and Inflammatory Cytokine Production In An Allogeneic Setting and Ameliorates Graft-Versus-Host Disease (GvHD) In a Murine GvHD Model (2013) (0)
[Immunocytologic diagnosis of leukemia and lymphoma: monoclonal antibodies in the differential diagnosis of hematologic neoplasms]. (1985) (0)
Crossreactivity of HER2-specific cytotoxic T cell clones with other members of the HER family (2014) (0)
Proteins In Vitro with Melanoma-Derived Heat Shock Respond to Dendritic Cells Pulsed with Synthetic Peptides, but Fail to Stimulated by Dendritic Cells Loaded Cytotoxic T Cell Clones Are Melanoma-Reactive Class I-Restricted (2010) (0)
Addendum: Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β production (2013) (0)
The niche protects hematopoietic stem cells through cytokines which regulate DNA repair and cytoskeleton dynamics (2016) (0)
Different FLT3 Inhibitors Display Limited, Non-Overlapping Profiles of Specific FLT3-ITD Resistance Mutations in a Cell-Based Screen. (2007) (0)
The Value of Ifosfamide in the Treatment of Multiple Myeloma (1998) (0)
557 BBR 3576: phase I dose escalation study in patients with advanced solid tumors (a study with the participation of CESAR-EWIV) (2003) (0)
Phase-I study for definitive radiochemotherapy (RCT) with paclitaxel and cisplatin in locally advanced squamous cell cancers of the suprabifurcal oesophagus (2006) (0)
A Mouse Model for XLP-2 Disease Uncovers a Critical Function for IL-1beta and TNF in Driving Hyper-Inflammation (2014) (0)
GM1 Expression of Non-Hodgkins Lymphoma Determines Susceptibility to Rituximab Treatment. (2007) (0)
[Proliferation of myeloid precursor cells in a microagar culture system]. (1982) (0)
HAX1 is an essential regulator of CXCR4 endocytosis that determines sensitivity to BTK-inhibiton in B-cell lymphoma (2017) (0)
SCF(Fbxo25) suppresses B cell lymphomagenesis by targeting Hax-1 for ubiquitin mediated proteasomal degradation (2011) (0)
A Single Retroviral Vector Design for the Simultaneous Expression of a Mir30 Based Shrna with An Oncogene – Identification of Raf-1 but Not BRAF as a Crucial Mediator for BCR-ABL Mediated Leukemogenesis. (2010) (0)
Constitutive gp130-JAK-STAT3 Signaling Induces a Plasma Cell Disorder Representing Genetic and Clinical Features of Human Myeloma – a Novel in Vivo Model for the Patient Subgroup Characterized By a STAT3 Target Gene Signature (2014) (0)
[18F]FLT Is Superior to [18F]FDG to Early Predict Response to Specific Inhibitors of NPM-ALK-Dependent Pathways In a Human ALCL Xenograft Model (2010) (0)
Aurora kinases A and B are Myc targets essential for maintenance of the malignant state (2010) (0)
Randomized comparison of pegylated IFN-a2b versus IFN-a2b maintenance following tandem autologous transplant in multiple myeloma (2016) (0)
[Bone marrow culture, cytochemistry and electron microscopy in agar in patients with preleukemic syndrome and aplastic anemia]. (1982) (0)
Inhibition of NOD2 signalling by mutations in the RING domain of XIAP contribute to development of X-linked lymphoproliferative syndrome (2011) (0)
Myc Promotes Tumorigenesis by Supressing Nfkb2. (2006) (0)
Cross-React with HER 3 and HER 4 CTLs Directed against HER 2 Specifically (2008) (0)
Inactivation of NIPA Results in Premature Mitotic Entry and Subsequent Mitotic Catastrophe. (2005) (0)
study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with (2013) (0)
Response : The definition of resistance is in the eye of the beholder (2006) (0)
Acknowledgement to Reviewers (2007) (0)
Use of blood products in the management of chemotherapy induced hematotoxicity in NSCLC and lymphoma patients in germany (2007) (0)
Alloreactivity as a Source of High Avidity T Cell Clones Specific for Cancer Testis-Antigens Associated with Multiple Myeloma: Prospects for Adoptive Immunotherapy with Primary T Cells Redirected toward Multiple Myeloma by T Cell Receptor Gene Transfer. (2006) (0)
Tyrosine Kinase Inhibition by SU5614 Fails To Eradicate Leukemic Stem Cells in FLT3-ITD+ Acute Myeloid Leukemia: Role of the Microenvironment. (2007) (0)
Transforming growth factor beta is an autocrine inhibitor of proliferation of chronic lymphocytic leukemia B cells (1995) (0)
Abstract A005: Tumor- and host-intrinsic RIG-I signaling promote anticancer immunity by CTLA-4 blockade (2016) (0)
Subpopulations of colony-forming B lymphocytes exhibit distinct in vitro growth characteristics. (1984) (0)
the mutation pattern for PD166326, an alternative Abl kinase inhibitor A cell-based screen for resistance of Bcr-Abl positive leukemia identifies (2012) (0)
reduced expression of cyclin D3, cyclin E, cyclin A and survivin Rapamycin induced G1 arrest in cycling B-CLL cells is associated with (2013) (0)
Antifungal Therapy with Itraconazole Impairs Rituximab′s Anti-Lymphoma Effect by Inhibiting CD20 Recruitment to Lipid Rafts. (2009) (0)
OC-0094: Cancer Clinical Trials - survey evaluating patient participation and attitude in an Oncology Center (2018) (0)
PCN42 COST ANALYSIS OF SEPSIS MANAGEMENT AFTER MYELOSUPPRESSIV CHEMOTHERAPY IN NSCLC AND LYMPHPOMA PATIENTS: A GERMAN HOSPITAL PERSPECTIVE (2007) (0)
Cathepsin K maintains the compartment of bone marrow T lymphocytes in vivo (2021) (0)
WNT5A from the niche regulates the actin regulatory pathway in hematopoietic stem cells (2016) (0)
Recombinant interferon beta in chronic myelogenous leukemia. (1993) (0)
Stimulation of cord blood cells by stem cell factor and oncostatin m maintains NOD/SCID-repopulating cells (2005) (0)
The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism (2019) (0)
A phase I trial of PKC412, an inhibitor of protein kinase C, in combination with bolus 5-Fluorouracil and leucovorin in patients with stage IV colorectal cancer (2001) (0)
[Chemoimmunotherapy as a new strategy in chronic lymphocytic leukemia. German CLL study]. (2011) (0)
BCL-2 Inhibition by ABT-199 Potently Induces Cell Death in MDS Progenitors Despite High-Risk Mutations in ASXL1, RUNX1, TP53 or EZH2 (2017) (0)
Addition of the monoclonal Epidermal Growth Factor (EGF) receptor antibody cetuximab (E) to cisplatin/5-FU (CF) versus CF in 1st line Metastatic Squamous Cell Carcinoma of the esophagus (MESCC): First results of the phase II oesotux trial (2008) (0)
PS1327 PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML (2019) (0)
Frequency of Mesenchymal Colony-Forming Cells (CFU-F) from Human Cord Blood and the Umbilical Vein. (2005) (0)
The Combination of Stem Cell Factor and Oncostatin M Maintains Cord Blood-Derived NOD/SCID-Repopulating Cells. (2005) (0)
SRC Is a Critical Signaling Mediator in FLT3-ITD Positive AML. (2009) (0)
Connective Tissue Growth Factor (Ctgf/Ccn2) Is a Novel Extrinsic Niche-Derived Regulator Of Hematopoietic Stem Cells (2013) (0)
Abstract 1887: Targeting oncoprotein stability overcomes lapatinib-resistance due to ERBB2 kinase domain mutations (2012) (0)
NIPA As a Novel Regulator of Aging and Stress Response of the Primitive HSC Pool (2015) (0)
[A microagar culture system for clonal growth of human T-lymphocytes]. (1982) (0)
Altered adhesive properties of cord blood endothelial outgrowth cells expressing IL‐1ra (2010) (0)
Frequency and clonogenic capacity of the rare CFU-F subpopulation of Mesenchymal Stem Cells (MSC) is significantly reduced in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2016) (0)
Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells (2009) (0)
This mouse-model may give important insights into different aspects of CML-development Additionally it may help to elucidate mechanisms of drug resistance against for example the tyrosine kinase inhibitor STI571 Induction of leukemia in mice transplanted with EGFP-Bcr-Abl transduced bone-marrow (2000) (0)
A cell-based screening method for resistance of Bcr-Abl positive leukemia identifies the mutation pattern for an alternative abl kinase inhibitor. (2004) (0)
Phase I trial of continous infusion 5-fluorouracil (CI-5FU) and escalating doses of oxaliplatin (OXA) given weekly with concurrent radiation (RT) in locally advanced esophageal squamous cell carcinoma (ESCC) (2005) (0)
ZAP70 Integrates BCR-Signaling into Innate Signaling Pathways in CLL (2014) (0)
Impact of chemotherapy induced haematotoxicity on blood component use and associated costs in NSCLC and lymphoma patients in Germany (2008) (0)
Redirection of human T lymphocytes towards HER2 by T cell receptor gene transfer for adoptive T cell transfer (41.6) (2009) (0)
Functional and Molecular Analysis of Maturation of Thymocytes in Bcl10 or Malt1 Deficient Mice. (2005) (0)
Biotherapy of chronic myelogenous leukemia (1995) (0)
Early prediction of tumor response and overall survival in patients with non-small cell lung cancer by FDG-PET. (2003) (0)
kinase inhibitor AMN107 (nilotinib) The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine (2012) (0)
P70. Development of clinically implementable imaging strategies for tracking T cell receptor-transgenic T cells (2014) (0)
MCl-1 is critically required for T-lymphocyte non-Hodgkin lymphoma cell survival (2013) (0)
Unraveling STAT Signaling in NPM/ALK-Induced Lymphoma: STAT3 but Not STAT5 Is Required for Lymphomagenesis in a Bone Marrow Transplantation Model Using Conditional Knockout Mice. (2009) (0)
NIPA Phosphorylation and Inactivation at G2/M Is Mediated by ERK2. (2009) (0)
stem cells Stromal pleiotrophin regulates repopulation behavior of hematopoietic (2011) (0)
Grb10 Mediated Akt Activation Is Required for Induction of CML Like Myeloproliferative Disease in Mice by BCR-ABL. (2007) (0)
Loss Of NIPA Leads To Defects In The Repair Of DNA Double Strand Breaks In Mice (2013) (0)
Positron E mission T omography i n N on-Small-Cell L ung Cancer: P rediction o f R esponse t o C hemotherapy b y Quantitative A ssessment o f G lucose U se (2003) (0)
Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia (2018) (0)
Significantly Reduced CFU-F Frequency and Increased Adipogenic Differentiation of Mesenchymal Stem Cells (Msc) in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2017) (0)
Abstract #1766: Study of transforming potential and drug sensitivity of ErbB2 variants identifies lapatinib-resistant kinase domain mutations (2009) (0)
Transfusion, Volume 58, Number 7: (2018) (0)
XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma (2016) (0)
The F-Box Protein NIPA Regulates the Hematopoietic Stem Cell Pool (2011) (0)
LYMPHOID NEOPLASIA Integration of innate into adaptive immune responses in ZAP-70 – positive chronic lymphocytic leukemia (2016) (0)
[Structured patient education in oncology. A prospective study for implementing and effectiveness of interdisciplinary psycho-educational group intervention at a German university clinic]. (2002) (0)
The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2 (2019) (0)
IDENTIFICATION AND CHARACTERIZATION OF A NUCLEAR INTERACTING PARTNER OF ALK (NIPA) (2003) (0)
Induction of a cellular immune response against the tumor-associated antigen HER-2/neu using retrovirally transduced dendritic cells (1999) (0)
Rapid upregulation of CTGF under stress conditions is required for HSC maintenance through cross-talk of canonical Wnt and AKT signaling (2014) (0)
In-vivo proliferation imaging for early response assessment in patients with aggressive non-Hodgkins lymphoma (2011) (0)
Abstract 3952: Late Outgrowth Endothelial Progenitor Cells From Patients With AMI Improve Left Ventricular Ejection Fraction In Experimental Myocardial Infarction (2008) (0)
Azacitidine in Combination with the Selective FLT3 Kinase Inhibitor Crenolanib Effectively Disrupts Stromal Protection of CD34+ Leukemia-Initiating Cells (LIC) in FLT3-ITD+ Acute Myeloid Leukemia (AML) (2015) (0)
Inhibition of Protein Kinase C (PKC) delta with Rottlerin Induces Apoptosis in B-CLL Cells, Augments Chemotherapeutic Cytotoxicity and Inhibits Antiapoptotic Survival Signals. (2004) (0)
SMIF, a novel Smad4-interacting protein acts as a crucial transcriptional co-activator in TGFβ signalling. (2001) (0)
A cell-based screening strategy predicts Bcr-Abl mutations that cause resistance toward the second-generation Abl kinase inhibitor AMN107 (2005) (0)
Generation of HER2-reactive T helper and T killer cells: implementation for T cell therapy (2001) (0)
P69. Targeting naturally presented, leukemia-derived HLA ligands with TCR-transgenic T cells for the treatment of therapy refractory leukemias (2014) (0)
Osteoprogenitor SFRP1 prevents exhaustion of hematopoietic stem cells via PP2A-PR72/130-mediated regulation of p300 (2022) (0)
[Interferon-alpha in therapy of malignant hemoblastoses]. (1995) (0)
Rapid induction of a lymphoma-like disease in mice transplanted with NPM-ALK transduced bone marrow (2000) (0)
The Role of STAT5 in FLT3-Mediated Leukemogenesis (2012) (0)
Allele frequency of the JAK2 V617F mutation in chronic myeloproliferative disorders: homogeneous involvement of myeloid lineages, but infrequent detection in lymphocytes (2007) (0)
Vitamin D is Associated with Severity of Disease as Expressed by Subdiagnosis and IPSS-R in Patients with Myelodysplastic Syndromes (2017) (0)
Imatinib and Leptomycin B Are Effective in Overcoming Imatinib-Resistance Due to Bcr-Abl Amplification or Clonal Evolution but Not Due to Bcr-Abl Kinase Domain Mutation. (2005) (0)
The Economic Burden of Chemotherapy-Induced Toxicity in Lymphoma and NSCLC Routine Hospital Care (2008) (0)
Identification of secondary mutations leading to imatinib resistance in a murine model of CML by retrovirar insertional mutagenesis. (2003) (0)
Toxicity profile of a high-dose (HD) chemotherapy regimen with peripheral blood stem cell rescue (PBSCR) for adults with soft tissue sarcoma (STS) (1999) (0)
induction of interleukin-1 receptor antagonist marrow stromal cells: inhibition of hematopoietic growth factors and Regulation of cytokine expression by interferon-alpha in human bone (2011) (0)
The F-Box Protein NIPA Limits Hematopoietic Stem Cell Survival and Transplantation Efficiency (2013) (0)
A Role for NIPA in DNA Damage Response. (2004) (0)
Clonality analysis of lymphoid bone marrow infiltrates in chronic myeloproliferative disorders and myelodysplastic syndromes (2004) (0)
Abstract 3744: Local Transplantation Of Blood-derived Late-outgrowth Progenitor Cells Increased Reendothelialization, Inhibited Smooth Muscle Cell Proliferation And Reduced Neointima Formation After Experimental Carotid Injury (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christian Peschel?

Christian Peschel is affiliated with the following schools:

Christian Peschel's Academic­Influence.com Rankings

Christian Peschel's Degrees

Similar Degrees You Can Earn

Why Is Christian Peschel Influential?

Christian Peschel's Published Works

Published Works

What Schools Are Affiliated With Christian Peschel?

Christian Peschel's AcademicInfluence.com Rankings